Attovia Therapeutics Inc. (ATTO) carries a Roarable Rating of D (Sell) with 47/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Attovia Therapeutics Inc. (NASDAQ: ATTO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $15.27 (-3.35% 1D, market cap $697.1M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ATTO ranks #408 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ATTO carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, FDMT (4D Molecular Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -28.3%, cap $706.0M) and SLDB (Solid Biosciences Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $685.2M). Among the 5-stock peer group, ATTO leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).
Per ATTO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002058707), Attovia Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $165.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
SEC XBRL FY 2025 (10-K): 0.5% FCF Margin ($19.5M FCF) & 52% Gross Margin
Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)
While ATTO currently carries a cautious 47/100 (D) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($18.67) and Max Pain ($16.03) forces dealer call-delta covering toward $29.40.
Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Attovia Therapeutics Inc. (ATTO) dropped -3.35% to $15.27, trading at 15% of its 52-week range ($12.94 – $28). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
SAN CARLOS, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immu
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ATTO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ATTO. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Attovia Therapeutics Inc. (ATTO) ranks #408 by composite RQD confidence (47/100, grade D) and #400 by equity capitalization ($697.1M). Within this direct 5-issuer industry benchmark cohort, ATTO leads on earnings valuation at N/A trailing P/E, while FDMT leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. IAM currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with ATTO at 47/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ATTO
ACTIVE
Attovia Therapeutics Inc. | D | 47/100 | — | — | — | -3.35% | $697.1M | Benchmark Subject |
| FDMT 4D Molecular Therapeutics Inc. | D- | 40/100 | — | — | -28.3% | -1.16% | $706.0M | /fdmt-vs-atto → |
| SLDB Solid Biosciences Inc. | E | 31/100 | — | — | -35.0% | -1.39% | $685.2M | /sldb-vs-atto → |
| IAM Iambic Therapeutics Inc. | D | 50/100 | — | — | — | -3.38% | $676.9M | /iam-vs-atto → |
| CADL Candel Therapeutics Inc. | D- | 38/100 | — | — | -35.0% | -0.23% | $661.9M | /cadl-vs-atto → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Attovia Therapeutics Inc. (ATTO) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, ATTO closed FY2025 with $165.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | $0 | — | — | $165.9M | — |
As of 2026-11-01, Attovia Therapeutics Inc. (NASDAQ: ATTO) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 47/100 at a spot price of $15.27 (-3.35% 1D, market cap $697.1M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, ATTO ranks #408 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ATTO carries a Roarable D (47/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, FDMT (4D Molecular Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -28.3%, cap $706.0M) and SLDB (Solid Biosciences Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $685.2M). Among the 5-stock peer group, ATTO leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).
Per ATTO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002058707), Attovia Therapeutics Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $165.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
ATTO last traded at $15.27 (-3.35% on volume of 413,810 shares), positioning the stock -18.21% below its 50-day simple moving average ($18.67) and -19.76% below its 200-day simple moving average ($19.03). Across its 52-week range of $12.94 to $28.00, ATTO sits at the 15.5% percentile with a 14-day RSI of 43.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($13.36 to $17.18).
Why ATTO Stock dropped -3.35% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.